Everything below concerns WADA prohibited list. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
==== Actions ==== RO5203648 binds to the mouse, rat, cynomolgus monkey, and human TAAR1 all with high affinity (Ki = 0.5–6.8 nM). It is a potent partial agonist in all species (EC50Tooltip half-maximal effective concentration = 4.0 to 31 nM), with an efficacy of 48 to 73% relative to the endogenous TAAR1 agonists β-phenethylamine and tyramine and the TAAR1 full agonist RO5166017. RO5203648 is highly selective for the TAAR1, showing ≥130-fold selectivity for the mouse TAAR1 over 149 other targets.
23793Np + 4820Ca → 285113* → 282113 + 3 n Two atoms of 282113 were detected. The aim of this experiment had been to synthesise the isotopes 281113 and 282113 that would fill in the gap between isotopes produced via hot fusion (283113 and 284113) and cold fusion (278113). After five alpha decays, these nuclides would reach known isotopes of lawrencium, assuming that the decay chains were not terminated prematurely by spontaneous fission. The first decay chain ended in fission after four alpha decays, presumably originating from 266Db or its electron-capture daughter 266Rf. Spontaneous fission was not observed in the second chain even after four alpha decays. A fifth alpha decay in each chain could have been missed, since 266Db can theoretically undergo alpha decay, in which case the first decay chain would have ended at the known 262Lr or 262No and the second might have continued to the known long-lived 258Md, which has a half-life of 51.5 days, longer than the duration of the experiment: this would explain the lack of a spontaneous fission event in this chain. In the absence of direct detection of the long-lived alpha decays, these interpretations remain unconfirmed, and there is still no known link between any superheavy nuclides produced by hot fusion and the well-known main body of the chart of nuclides.
=== World War II === From the start of World War II in 1939, German ships used the gap to break out from their bases in northern Germany (and from occupied Norway after April 1940) with a view to attacking Allied shipping convoys, but Allied blocking efforts in the North Sea and in the GIUK gap impeded such break-outs. British forces occupied the Faroe Islands in April 1940, and Iceland in May 1940; the United States took over effective control of Greenland in 1940. But the German Kriegsmarine profited greatly from the fall of France in June 1940, after which German submarines could operate from bases on the French coast. The origin of the term "gap" dates to this period, when there was a gap in air coverage known as the Mid-Atlantic gap or the "Greenland air gap". This gap was an area that land-based aircraft could not reach and where, as a result, they could not carry out their anti-submarine duties.
2.A: Porters (uniporters, symporters, antiporters), SLCs. Excitatory amino acid transporters (EAATs) EAAT1 EAAT2 EAAT3 EAAT4 EAAT5 Glucose transporter Monoamine transporters, including: Dopamine transporter (DAT) Norepinephrine transporter (NET) Serotonin transporter (SERT) Vesicular monoamine transporters (VMAT) Adenine nucleotide translocator (ANT) 2.B: Nonribosomally synthesized porters, such as: The Nigericin family The Ionomycin family 2.C: Ion-gradient-driven energizers
S-Arrestin is a protein found in mice that binds to rhodopsin to stop its activity, preventing further signaling. S-arrestin binds to G protein-coupled receptors (GPCRs), like rhodopsin, following receptor activation and phosphorylation by G protein-coupled receptor kinases (GRKs). Rhodopsin is found in rod cells of the retina, essential for vision. It detects light and initiates a signaling cascade called phototransduction. However, excessive activation can be harmful, so it must be carefully regulated. The phosphorylation of the receptor's intracellular loops and C-terminal tail creates a high-affinity binding site for S-arrestin. S-arrestin then sterically hinders further G protein coupling, effectively desensitizing the receptor and directing it towards alternative signaling pathways or internalization via clathrin-mediated endocytosis.
Sources: en.wikipedia.org
Technetium-99 (99Tc) is an isotope of technetium that decays with a half-life of 211,000 years to stable ruthenium-99, emitting beta particles, but effectively no gamma rays. It is the most significant long-lived fission product of uranium fission, and the largest single contributor to the long-lived radioactivity of nuclear waste. Technetium-99 has a fission product yield of 6.0507% for thermal neutron fission of uranium-235. The metastable technetium-99m (99mTc) is a short-lived (half-life about 6 hours) nuclear isomer used in nuclear medicine, produced from molybdenum-99. It decays by isomeric transition to technetium-99, a desirable characteristic, since the very long half-life and type of decay of technetium-99 imposes little further radiation burden on the body.
== Research == Combination of insulin with sotaglifozin led to a significant lowering of systolic and diastolic blood pressure and multiple indirect markers of arterial stiffness, including pulse pressure, without changes in pulse rates.
==== September 2008 ==== On 1 September 2008, journalist of Nezavisimaya Gazeta wrote: "As early as 6 August I saw our army in full combat readiness near the Georgian border." On 2 September 2008, it was reported that several soldiers' mothers had sent letter to Commissioner for Human Rights in Perm Krai. One mother wrote that on 3 August his son said his unit might be deployed to the border. Another mother said that his son told her on 9 August that his unit was sent to South Ossetia on the evening of 7 August. On 11 September 2008, Yulia Latynina wrote that journalists who were sent in advance to cover the war reported on 6 August 2008 that they have seen "58th Army in full combat readiness on the other [Georgian] side of the Roki tunnel". On 15 September 2008, Novaya Gazeta reported that the South Ossetian soldier had told journalist that after the end of "Kavkaz 2008" exercises 80 tanks remained in South Ossetia. Journalist had also spoken with several Russian soldiers during her visit and they said they had been based in South Ossetia for a month, since 6 August 2008. The journalist noted that the Russian forces did not officially participate in the battle for Tskhinvali on 8 August, apparently waiting until the Georgian troops take the city, so later they could destroy both Tskhinvali and the Georgians. The construction of the road from Tskhinvali to Akhalgori had started 2 years ago.
Capstone Project MS degree: MS degree in pharmaceutical sciences with emphasis in cosmetic science (30 credit hours) Graduate Certificate (GC) in Cosmetic Science: 12 credit hours covering skin and hair science as well as formulation science MS and PhD degrees: intensive research-based MS and PhD degrees in pharmaceutical science with emphasis in cosmetic science (on-site at Cincinnati) Courses for non-matriculated students: Online courses are available to non-matriculated students who have not applied for acceptance into the GC or MS Programs (a maximum of six (6) semester credit hours may be transferred to either program upon matriculation). The graduate programs in cosmetic science grew from 17 students in 2013 to 96 students in 2017.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.